Takeda takes a swing at RNA small molecules with discovery pact for multiple potential Evotec programs
Heartened by an FDA approval for Roche’s Evrysdi last year as the first small molecule modulator for RNA, the rest of biopharma is looking …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
